stockrowTravere Therapeutics, Inc.
TVTX Healthcare Biotechnology
Travere Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $490.7 million, up 110.5% from fiscal 2024.
- Revenue
- +36.2%
- EPS
- −290.7%
- Free cash flow
- +6,379.8%
- Total debt
- +93.8%
Quarter to September 2026, against a year earlier
Follow TVTX
Alert me
Travere Therapeutics, Inc. (TVTX) Net income
Travere Therapeutics, Inc.'s net income for fiscal 2025 was −$25.5M, compared with −$321.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$121.5M. Over the past ten years it has ranged from −$321.5M (fiscal 2024) to $117.2M (fiscal 2015); the current reading is higher than 91% of that period. Travere Therapeutics, Inc. ranks 453rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$25.5M | — |
| FY2024 | −$321.5M | — |
| FY2023 | −$111.4M | — |
| FY2022 | −$278.5M | — |
| FY2021 | −$180.1M | — |
| FY2020 | −$169.4M | — |
| FY2019 | −$146.4M | — |
| FY2018 | −$102.7M | — |
| FY2017 | −$59.7M | — |
| FY2016 | −$47.9M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$52.3M | — |
| Jun 2026 | −$34.8M | — |
| Mar 2026 | −$37.1M | — |
| Dec 2025 | $2.7M | (89.38%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $1.0B |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| TVTX Travere Therapeutics, Inc. | −$121.5M |
| MANE Veradermics Incorporated compare | −$136.4M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| ERAS Erasca, Inc. compare | −$287.2M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| CRSP CRISPR Therapeutics AG compare | −$456.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TVTX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement